The American Heart Association and three other leading medical societies want clinicians to consider the heart health of women during all stages of life, from adolescence to menopause and beyond.

Metformin is typically the therapy of choice for patients with prediabetes, but GLP-1 drugs appear to offer several benefits.

“A drug that can both decrease the risk for diabetes along with the risk for having a heart attack or stroke could be a turning point in our ability to safely treat this growing population in the U.S. and abroad,” one researcher said.

“We expected that the chances of heart disease would gradually rise as people used cannabis more often, but that wasn’t the case," one researcher said. "Both low-use and heavy-use groups had higher odds of developing heart disease."

The product at the heart of this recall is a dietary supplement taken to boost energy and performance when exercising. The FDA previously warned the public not to take it due to the potential side effects. 

Researchers reviewed an FDA safety database, finding that these products were commonly involved in reports related to cardiac arrest, heart attacks, ventricular arrhythmias, heart palpitations, chest pain and fainting.

These findings call into question the types of screenings firefighters should undergo to detect potential heart problems.

The American College of Cardiology is pointing to the importance of prescribing exercise to heart patients. "Small increases in physical activity can produce meaningful benefits, particularly for those who are currently inactive," one expert explained. 

Orforglipron was linked to consistent weight loss in addition to reductions in waist circumference, systolic blood pressure, triglycerides, non-HDL cholesterol and high-sensitivity C-reactive protein. In terms of safety, it was found to be noninferior to insulin glargine.